Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beckman Coulter Inc.

Division of Danaher Corp.
www.beckmancoulter.com

Latest From Beckman Coulter Inc.

Device/Diagnostics Quarterly Deal-Making Statistics, Q3 2017

Third-quarter device financing at $2.38 billion – almost half of that amount from CooperSurgical's $1.1 billion bridge loan – was double the Q2 total, while device acquisitions showed a steep decrease at $3.38 billion versus Q2's $33.4 billion. Diagnostics fundraising also was up in the third quarter, reaching $2.4 billion (a 133% increase over Q2) mostly from Thermo Fisher Scientific's $1.5 billion follow-on offering, which accounted for 63% of the total. In line with the previous quarter's $1.7 billion in M&A, Q3 diagnostics acquisitions had an aggregate value of $1.8 billion, led by Konica Minolta's $1 billion buy of Ambry Genetics.

Medical Device In Vitro Diagnostics

US FDA Willing And Ready To Approve Novel Cardiac Troponin Assays

Rumors that FDA has raised the bar too high for clearing cardiac troponin assays to predict myocardial infarction "are not true," a device center reviewer said at an agency workshop. FDA is open to novel tests and wants industry to give it direction on clinically meaningful cut-off levels of troponin for assays. Also, FDA issued a safety alert on consumer overuse of Biotin (Vitamin B7) for aesthetic purposes, which can interfere with the results of the assays.

In Vitro Diagnostics Research and Development Strategies

Antimicrobial Susceptibility Test-Makers Seek Ways To Shorten FDA Clearance Process

A group of antimicrobial susceptibility test manufacturers are working with US FDA regulators to hasten the clearance process for their products. The agency recent convened a workshop at its Maryland headquarters to help address the issue.

In Vitro Diagnostics Regulation

M&A Analysis: July M&A Levels Reach Fever Pitch

The summer season is proving to be a hot one for medtech M&A activity, with another busy month of deal-making in July. Twenty-five deals were announced and closed during the month, surpassing June's deal count and making it the month with the highest M&A activity to date.

M & A Deals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register